位置:首页 > 产品库 > Dactolisib Tosylate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Dactolisib Tosylate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Dactolisib Tosylate图片
CAS NO:1028385-32-1

BEZ235 Tosylate
NVP-BEZ 235 Tosylate
Dactolisib Tosylate (BEZ235 Tosylate) 是PI3KmTOR的双重激酶抑制剂,对PI3Kα, β, γ, δ 的IC50值分别为4, 75, 7, 5 nM。Dactolisib Tosylate (BEZ235 Tosylate) 抑制mTORC1mTORC2
生物活性

Dactolisib Tosylate (BEZ235 Tosylate) is a dualPI3KandmTORkinase inhibitor withIC50values of 4, 75, 7, 5 nM forPI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibitsmTORC1andmTORC2.

IC50& Target[1]

p110α

4 nM (IC50)

p110α-H1047R

4.6 nM (IC50)

p110α-E545K

5.7 nM (IC50)

p110γ

5 nM (IC50)

p110δ

7 nM (IC50)

p110β

75 nM (IC50)

mTOR

20.7 nM (IC50)

mTORC1

 

mTORC2

 

Autophagy

 

体外研究
(In Vitro)

Dactolisib (BEZ235) is an imidazo[4,5-c]quinoline derivative that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. The IC50s for PI3Kα, β, γ, δ are 4, 75, 7, 5 nM, respectively. It is also found to be as active against the mutant PI3KαE545Kor PI3KαH1047Rwith IC50s of 5.7 and 4.6 nM, respectively. In human tumor cell lines, it is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest. PTEN-null cell lines PC3M and U87MG shows a dose-dependent reduction in cell proliferation when treated with increasing concentrations of Dactolisib (BEZ235), with an average GI50of 10 to 12 nM[1].

体内研究
(In Vivo)

Dactolisib (BEZ235) is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents. At a dose of 50 mg/kg, Dactolisib (BEZ235) appears rapidly in plasma with a Cmaxof 1.68 μM at 0.5 h and a C24hof 0.03 μM[1].

Clinical Trial
分子量

641.74

性状

Solid

Formula

C37H31N5O4S

CAS 号

1028385-32-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 34 mg/mL(52.98 mM;Need ultrasonic and warming)

H2O :< 0.1 mg/mL(insoluble)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM1.5583 mL7.7913 mL15.5826 mL
5 mM0.3117 mL1.5583 mL3.1165 mL
10 mM0.1558 mL0.7791 mL1.5583 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 50%PEG300   50% saline

    Solubility: 16.67 mg/mL (25.98 mM); Suspended solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂: 10% DMSO    90%corn oil

    Solubility: ≥ 1 mg/mL (1.56 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (1.56 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在本网站选购。
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024